July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Progression of Diabetic Retinopathy Severity after Treatment
with Dexamethasone Implant – A 24-Month Cohort Study
The ‘DR-Pro-DEX Study’
Author Affiliations & Notes
  • Matias Iglicki
    University of Buenos Aires , Caba, Argentina
  • Dinah Zur
    Division of Ophthalmology, , Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel Aviv, Israel
  • Catharina Busch
    Ophthalmology , Department of Ophthalmology, University of Leipzig, Germany, Leipzig, Germany
  • Mali Okada
    Royal Victorian Eye and Ear Hospital, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia , Melbourne, Victoria, Australia
  • Anat Loewenstein
    Division of Ophthalmology, , Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Tel Aviv, Israel
    Incumbent, Sydney A. Fox chair in Ophthalmology, Incumbent, Sydney A. Fox chair in Ophthalmology, Tel Aviv University, Tel Aviv, Israel, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Matias Iglicki, None; Dinah Zur, None; Catharina Busch, None; Mali Okada, None; Anat Loewenstein, None
  • Footnotes
    Support  NONE
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 6001. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Matias Iglicki, Dinah Zur, Catharina Busch, Mali Okada, Anat Loewenstein; Progression of Diabetic Retinopathy Severity after Treatment
      with Dexamethasone Implant – A 24-Month Cohort Study
      The ‘DR-Pro-DEX Study’. Invest. Ophthalmol. Vis. Sci. 2018;59(9):6001.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : While intravitreal anti-vascular endothelial growth factor agents have recently been shown to reduce progression of diabetic retinopathy (DR), data on the effects of intravitreal corticosteroids on modifying disease severity is limited. This study evaluates the long-term effect of intravitreal dexamethasone implant (DEX) on the severity and progression of non proliferative DR (NPDR).

Methods : This was a retrospective cohort study of patients with NPDR and diabetic macular edema (DME) treated with as required dexamethasone implant (DEX-group) compared to controls without DME requiring observation only with a follow-up of 24 months. Outcome measures included change of DR ≥ 1 grade and progression to proliferative diabetic retinopathy (PDR).

Results : 109 eyes from 109 patients were included: 60 eyes in the DEX-group and 49 control eyes. Three eyes (5%) in the DEX-group, and 43 (87.8%) eyes in the control group progressed to PDR (p< 0.0001). Twenty-five eyes (41.7%) in the DEX group but none in the control group demonstrated an improvement in DR severity (p < 0.0001).

Conclusions : This study provides the first long-term evidence that DEX implant has the potential to not only delay progression of DR and PDR development, but may also improve DR severity over 24 months. Better understanding of the effects of corticosteroids will help guide its use in the treatment pathway of DR.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Fig. 1 Change in severity of diabetic retinopathy (DR) at 24 months follow-up stratified for baseline DR severity. DEX-group – subjects with non-proliferative diabetic retinopathy (NPDR) and diabetic macula edema (DME), treated with dexamethasone implant; Control Group – Subjects with NPDR without DME.

Fig. 1 Change in severity of diabetic retinopathy (DR) at 24 months follow-up stratified for baseline DR severity. DEX-group – subjects with non-proliferative diabetic retinopathy (NPDR) and diabetic macula edema (DME), treated with dexamethasone implant; Control Group – Subjects with NPDR without DME.

 

FIg. 2 Change in severity of diabetic retinopathy (DR) at 24 months follow-up. DEX-group (n=60) – Patients with non-proliferative diabetic retinopathy (NPDR) and diabetic macula edema (DME), treated with dexamethasone implant, Control (n=49) – Patients with NPDR without DME. Numbers of patients are indicated above each bar.

FIg. 2 Change in severity of diabetic retinopathy (DR) at 24 months follow-up. DEX-group (n=60) – Patients with non-proliferative diabetic retinopathy (NPDR) and diabetic macula edema (DME), treated with dexamethasone implant, Control (n=49) – Patients with NPDR without DME. Numbers of patients are indicated above each bar.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×